Kyowa partners with Ultragenyx for rare bone disease product

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) partnered with Ultragenyx Pharmaceutical Inc. (Novato, Calif.) to co-develop and co-commercialize KRN23, which is in development for X-linked hypophosphatemia (XLH). Under the deal, Ultragenyx will lead development for KRN23 and the partners will share costs in the U.S., Canada and EU. The companies will co-commercialize KRN23 in the U.S. and Canada, and Kyowa will commercialize the compound in the EU. Ultragenyx will be solely responsible for development and commercialization in Mexico and Central and South America, and Kyowa will retain rights to KRN23 elsewhere. Financial details of the deal are not disclosed. ...